Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases

Cosimo Colletta, Carlo Smirne, Carlo Fabris, Pierluigi Toniutto, Rachele Rapetti, Rosalba Minisini, Mario Pirisi – 24 August 2005 – The course of hepatitis C virus (HCV) infection carriers with normal/near‐normal aminotransferases (NALT) is usually mild; however, in a few, fibrosis progression occurs. We aimed to verify whether monitoring by liver biopsy might be replaced by noninvasive methods and to identify factors associated with fibrosis progression in patients with persistently normal alanine aminotransferases.

Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection

Yves Horsmans, Thomas Berg, Jean‐Pierre Desager, Tobias Mueller, Eckart Schott, Simon P. Fletcher, Kevin R. Steffy, Lisa A. Bauman, Bradley M. Kerr, Devron R. Averett – 22 August 2005 – Immune‐based therapy is the mainstay treatment for chronic hepatitis C virus (HCV) infection but causes multiple side effects and achieves durable viral clearance in only approximately 50% of patients. Most new investigational anti‐HCV compounds are direct‐acting antivirals for which durability of response and risk of viral mutations and resistance are not yet known.

Glutathione depletion renders rat hepatocytes sensitive to nitric oxide donor–mediated toxicity

Tracy Chen, Linda L. Pearce, Jim Peterson, Detcho Stoyanovsky, Timothy R. Billiar – 22 August 2005 – Nitric oxide (NO) can be either cytoprotective or cytotoxic in hepatocytes, depending on conditions within the cell. We hypothesized that redox status is a determinant of NO effects on cell viability.

Function follows form: The structure of the N‐terminal domain of HCV NS5A

Darius Moradpour, Volker Brass, Francois Penin – 22 August 2005 – Hepatitis C virus (HCV) is a human pathogen affecting nearly 3% of the world's population. Chronic infections can lead to cirrhosis and liver cancer. The RNA replication machine of HCV is a multi‐subunit membrane‐associated complex. The nonstructural protein NS5A is an active component of HCV replicase, as well as a pivotal regulator of replication and a modulator of cellular processes ranging from innate immunity to dysregulated cell growth.

Subscribe to